Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3914-8171
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.89 billion
Profitability
Miscellaneous
Employees42,535
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its quarterly earnings results on Wednesday, February, 12th. The company reported $0.62 EPS for the quarter, topping the Zacks' consensus estimate of $0.61 by $0.01. The company had revenue of $4.47 billion for the quarter, compared to analysts' expectations of $4.35 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.49% and a negative net margin of 5.75%. Teva Pharmaceutical Industries's revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the business earned $0.53 earnings per share. View Teva Pharmaceutical Industries' Earnings History.
When is Teva Pharmaceutical Industries' next earnings date?
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?
Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided EPS guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.47. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $17.14 billion.
What price target have analysts set for TEVA?
23 equities research analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' stock. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.75 in the next year. This suggests that the stock has a possible downside of 8.7%. View Analyst Price Targets for Teva Pharmaceutical Industries.
What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.
Has Teva Pharmaceutical Industries been receiving favorable news coverage?
News coverage about TEVA stock has been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Teva Pharmaceutical Industries.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Mylan (MYL) and Beigene (BGNE).
What other stocks do shareholders of Teva Pharmaceutical Industries own?
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
- Mr. Michael McClellan, Exec. VP & CFO (Age 48)
- Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
- Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
- Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)
Who are Teva Pharmaceutical Industries' major shareholders?
Teva Pharmaceutical Industries' stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital Research Global Investors (11.99%), Franklin Resources Inc. (1.82%), Migdal Insurance & Financial Holdings Ltd. (1.16%), Menora Mivtachim Holdings LTD. (0.77%), Commerzbank Aktiengesellschaft FI (0.72%) and Phoenix Holdings Ltd. (0.60%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Which major investors are selling Teva Pharmaceutical Industries stock?
TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Renaissance Technologies LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Commerzbank Aktiengesellschaft FI, Acadian Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, Janus Henderson Group PLC and Cubist Systematic Strategies LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Which major investors are buying Teva Pharmaceutical Industries stock?
TEVA stock was purchased by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Migdal Insurance & Financial Holdings Ltd., Harel Insurance Investments & Financial Services Ltd., Phoenix Holdings Ltd., Banco Bilbao Vizcaya Argentaria S.A., Beck Mack & Oliver LLC, Van ECK Associates Corp and UBS Asset Management Americas Inc.. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy shares of Teva Pharmaceutical Industries?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of TEVA stock can currently be purchased for approximately $12.86.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $14.05 billion and generates $16.89 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.
What is Teva Pharmaceutical Industries' official website?
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
